Mirabegron - ≥99%, high purity , Beta-3 adrenergic receptor agonist, CAS No.223673-61-8, Beta-3 adrenergic receptor agonist

Item Number
M126688
Grouped product items
SKUSizeAvailabilityPrice Qty
M126688-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$86.90
M126688-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$151.90
M126688-50mg
50mg
In stock
$489.90
M126688-250mg
250mg
In stock
$2,205.90
M126688-1g
1g
In stock
$7,938.90
M126688-5g
5g
In stock
$35,721.90
M126688-25g
25g
In stock
$160,744.90

Potent and selective β3agonist

Basic Description

Synonyms4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)- | NCGC00386239-01 | A816162 | CHEBI:92250 | Q3702534 | AB01565808_02 | MFCD02102216 | Myrbetriq (TN) | s4009 | UNII-868YEO5270 | YM 178;2-(2-aminothiazol-4-yl)-N-[4-[
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsPotent and selective β3-adrenoceptor agonist (EC50= 22.4 nM). Displays >440-fold selectivity for β3over β1and β2adrenoceptors. Increases cAMP concentration in CHO cells expressing human β3-adrenoceptor. Displays relaxant effect inex vivorat bladder muscle
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionBeta-3 adrenergic receptor agonist
Product Description

A potent bladder relaxant and reagent for diabetes remedy.
A potent bladder relaxant compound

Product Properties

ALogP2.1

Associated Targets(Human)

ADRB2 Tclin Beta-2 adrenergic receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADRB3 Tclin Beta-3 adrenergic receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADRB1 Tclin Beta-1 adrenergic receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK1D Tchem Casein kinase I delta (4546 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
S1PR1 Tclin Sphingosine 1-phosphate receptor Edg-1 (5806 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK2 Tchem Cyclin-dependent kinase 2 (9050 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GLP1R Tclin Glucagon-like peptide 1 receptor (111429 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
C5AR1 Tclin C5a anaphylatoxin chemotactic receptor (2677 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKA Tchem Serine/threonine-protein kinase Aurora-A (10240 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U2OS (164939 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CX3CR1 Tchem C-X3-C chemokine receptor 1 (1686 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FPR2 Tchem Lipoxin A4 receptor (3472 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FFAR4 Tchem G-protein coupled receptor 120 (2999 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BRD4 Tchem Bromodomain-containing protein 4 (13122 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GPR35 Tchem G-protein coupled receptor 35 (2643 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TRIM24 Tchem Transcription intermediary factor 1-alpha (2087 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BRPF1 Tchem Peregrin (2217 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK-293T (167025 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Aplnr Apelin receptor (201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr3 Fibroblast growth factor receptor 3 (21 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Canis familiaris (36305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Gpr119 Glucose-dependent insulinotropic receptor (270 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (328 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
INCHI InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChi Key PBAPPPCECJKMCM-IBGZPJMESA-N
Canonical SMILES C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
Isomeric SMILES C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
PubChem CID 9865528
Molecular Weight 396.51

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot NumberCertificate TypeDateItem
G2215379Certificate of AnalysisApr 07, 2024 M126688
G2215380Certificate of AnalysisApr 07, 2024 M126688
G2215381Certificate of AnalysisApr 07, 2024 M126688
G2215777Certificate of AnalysisApr 07, 2024 M126688
G2215778Certificate of AnalysisApr 07, 2024 M126688
H1505066Certificate of AnalysisMar 16, 2023 M126688
A2128196Certificate of AnalysisDec 08, 2022 M126688
L2209023Certificate of AnalysisJun 01, 2022 M126688
L2209024Certificate of AnalysisJun 01, 2022 M126688
L2209025Certificate of AnalysisJun 01, 2022 M126688

Chemical and Physical Properties

SolubilitySolvent:DMSO, Max Conc. mg/mL: 39.65, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 7.93, Max Conc. mM: 20

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS09,   GHS07
Signal Warning
Hazard Statements

H319:Causes serious eye irritation

H351:Suspected of causing cancer

H373:Causes damage to organs through prolonged or repeated exposure

H302:Harmful if swallowed

H317:May cause an allergic skin reaction

H410:Very toxic to aquatic life with long lasting effects

H361:Suspected of damaging fertility or the unborn child

H371:May cause damage to organs

H362:May cause harm to breast-fed children

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P273:Avoid release to the environment.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352:IF ON SKIN: wash with plenty of water.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P270:Do not eat, drink or smoke when using this product.

P272:Contaminated work clothing should not be allowed out of the workplace.

P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention.

P362+P364:Take off contaminated clothing and wash it before reuse.

P391:Collect spillage.

P330:Rinse mouth.

P263:Avoid contact during pregnancy/while nursing.

P203:Obtain, read and follow all safety instructions before use.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P301+P317:IF SWALLOWED: Get medical help.

P318:if exposed or concerned, get medical advice.

P337+P317:If eye irritation persists: Get medical help.

P308+P316:IF exposed or concerned: Get emergency medical help immediately.

P319:Get medical help if you feel unwell.

Related Documents

Citations of This Product

1. Yutao Lou, Mengting Cheng, Qin Cao, Kening Li, Hui Qin, Meihua Bao, Yuan Zhang, Sisi Lin, Yiwen Zhang.  (2023)  Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder.  JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,    (115937).  [PMID:38198885] [10.1016/j.jpba.2023.115937]

References

1. Yamaguchi O.  (2002)  Beta3-adrenoceptors in human detrusor muscle..  Urology,  59  (5 Suppl 1): (25-9).  [PMID:12007519] [10.1021/op500134e]
2. Nomiya M, Yamaguchi O.  (2003)  A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders..  J Urol,  170  (2 Pt 1): (649-53).  [PMID:12853849] [10.1021/op500134e]
3. Badawi JK, Seja T, Uecelehan H, Honeck P, Kwon ST, Bross S, Langbein S.  (2007)  Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines..  Urology,  69  (4): (785-90).  [PMID:17445682] [10.1021/op500134e]
4. Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS.  (2018)  Mirabegron: potential off target effects and uses beyond the bladder..  Br J Pharmacol,  175  (21): (4072-4082).  [PMID:29243229] [10.1021/op500134e]
5. Yutao Lou, Mengting Cheng, Qin Cao, Kening Li, Hui Qin, Meihua Bao, Yuan Zhang, Sisi Lin, Yiwen Zhang.  (2023)  Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder.  JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,    (115937).  [PMID:38198885] [10.1016/j.jpba.2023.115937]

Solution Calculators